New antibody cocktail targets Hard-to-Treat prostate cancer
NCT ID NCT06866548
First seen Jan 11, 2026 · Last updated May 17, 2026 · Updated 19 times
Summary
This early-stage trial tests whether combining two lab-made antibodies can help control metastatic castration-resistant prostate cancer (mCRPC), a tough-to-treat form of prostate cancer. Seven men with advanced disease will receive the drug combo and be monitored for side effects and signs of tumor progression. The goal is to see if the treatment is safe and slows the cancer's growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MCRPC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Shanghai Changzheng Hospital
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.